Regulatory considerations for developing remote measurement technologies for Alzheimer's disease research.

BORIS DOI
Date of Publication
September 4, 2024
Publication Type
Article
Division/Institute

University Hospital o...

Contributor
Erdemli, Gül
Grammatikopoulou, Margarita
Wagner, Bertil
Vairavan, Srinivasan
Curcic, Jelena
Aarsland, Dag
Wittenberg, Gayle
Nikolopoulos, Spiros
Muurling, Marijn
Froehlich, Holger
de Boer, Casper
Shanbhag, Niraj M
Nies, Vera J M
Coello, Neva
Gove, Dianne
Diaz, Ana
Foy, Suzanne
Dartee, Wim
Subject(s)

600 - Technology::610...

Series
npj Digital Medicine
ISSN or ISBN (if monograph)
2398-6352
Publisher
Nature Research
Language
en
Publisher DOI
PubMed ID
39232033
Description
The Remote Assessment of Disease and Relapse – Alzheimer’s Disease (RADAR-AD) consortium evaluated remote measurement technologies (RMTs) for assessing functional status in AD. The consortium engaged with the European Medicines Agency (EMA) to obtain feedback on identification of meaningful functional domains, selection of RMTs and clinical study design to assess the feasibility of using RMTs in AD clinical studies. We summarized the feedback and the lessons learned to guide future projects.
Handle
Show full item
File(s)
FileFile TypeFormatSizeLicensePublisher/Copright statementContent
s41746-024-01211-8.pdftextAdobe PDF710.61 KBAttribution-NonCommercial-NoDerivatives (CC BY-NC-ND 4.0)publishedOpen